Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Shoulder Innovations, Inc.NYSE: SI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.68M, compared with -$3.63M a year earlier. Trailing-twelve-month EBITDA was -$41.14M.
Context
- EBITDA amounted to 78.4% of revenue in FY2025, up 40.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$29.67M (+20.0%) for the fiscal year ending Dec 2026, a step up from the -206.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.68M-4.1% QoQ
- Last fiscal yearDec 2025
- -$37.08M-206.3% YoY
- LTMMar 2026
- -$41.14M-191.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -111.8% | +53.9% | +165.7 pp |
| 1 year | -206.3% | +20.0% | +226.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (37.08M) USD
- Year-over-year change
- -206.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (37.08M) | -206.3% |
| FY2024 | 2024-12-31 | (12.11M) | -18.1% |
| FY2023 | 2023-12-31 | (10.25M) | — |
EBITDA vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 EBITDA of -$41.14M is the 5th highest of the 11 companies compared; the peer median is -$46.02M.
- Its year-over-year change of -191.1% is the lowest of 11, against a peer median of +24.1%.
- EBITDA amounts to 76.3% of revenue for SI, versus a peer median of 51.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.67M | +217.1% | +59.4% | 51.1% | |
| LTM Mar 2026 | -$5.23M | +26.2% | — | 1.5% | |
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
| FY2025 | -$14.01M | +36.4% | — | 13.0% | |
| LTM Mar 2026 | -$41.14M | -191.1% | — | 76.3% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M | -75.7% | — | — |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Dec 2025 | -$49M | -11.0% | — | 376.3% | |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$62.35M | +22.0% | — | 53.0% | |
| LTM Mar 2026 | -$69.83M | -147.0% | — | — | |
| Peer median (excluding SI) | -$46.02M | +24.1% | +59.4% | 51.1% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 19.27M | 31.62M | 47.32M |
| Cost of Revenue | 4M | 7.28M | 11.12M |
| Gross Profit | 15.27M | 24.34M | 36.2M |
| Gross Margin | 79.2% | 77.0% | 76.5% |
| Research & Development | 3.02M | 4.49M | 7.73M |
| Selling, General & Admin | 23.11M | 34.51M | 54.77M |
| Operating Expenses | 26.13M | 38.99M | 62.5M |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| EBITDA | (10.25M) | (12.11M) | (37.08M) |
| EBITDA Margin | -53.2% | -38.3% | -78.4% |
| Operating Income | (10.86M) | (14.65M) | (26.3M) |
| Operating Margin | -56.4% | -46.3% | -55.6% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 761K | 1.32M | 70K |
| Other Income / Expenses | (1.79M) | (966K) | (14.06M) |
| Income Before Tax | (12.66M) | (15.62M) | (40.36M) |
| Pre-Tax Margin | -65.7% | -49.4% | -85.3% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Net Margin | -65.7% | -49.4% | -85.3% |
| EPS (Basic) | (0.63) | (0.77) | (1.96) |
| EPS (Diluted) | (0.63) | (0.77) | (1.96) |
| Weighted Avg Shares | 19.92M | 19.92M | 20.63M |
| Weighted Avg Shares (Diluted) | 19.92M | 19.92M | 20.63M |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.